Skip to main content

Peer Review reports

From: Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Original Submission
17 Aug 2017 Submitted Original manuscript
13 Sep 2017 Author responded Author comments - Catja Freiburghaus
Resubmission - Version 2
13 Sep 2017 Submitted Manuscript version 2
17 Oct 2017 Reviewed Reviewer Report - Shannon Buckley
30 Oct 2017 Reviewed Reviewer Report - Bhopal Mohapatra
20 Nov 2017 Author responded Author comments - Catja Freiburghaus
Resubmission - Version 3
20 Nov 2017 Submitted Manuscript version 3
3 Jan 2018 Reviewed Reviewer Report - Samir Parekh
25 Mar 2018 Author responded Author comments - Catja Freiburghaus
Resubmission - Version 4
25 Mar 2018 Submitted Manuscript version 4
Publishing
8 Apr 2018 Editorially accepted
25 Apr 2018 Article published 10.1186/s12885-018-4346-1

You can find further information about peer review here.

Back to article page